Charlie Gourley Research Group

Ovarian cancer is the sixth most common cause of female cancer death in the UK. Until recently it has been treated as a single disease entity. There is now considerable evidence to demonstrate that ovarian cancers differ in their tissues of origin, their genetic abnormalities, their responsiveness to chemotherapy and the ultimate outcome for patients. 

We are investigating the biology of this disease at the interface between the laboratory and the clinic in order to generate findings that can be directly translated into patient benefit. We do this by characterising the molecular changes that occur in different ovarian cancers and determining how this affects their responsiveness to chemotherapy or novel biological agents.

• International Consortium for Low-Grade Serous Ovarian Cancer  (ICLC): The University of Texas M. D. Anderson Cancer Centre, Memorial Sloan Kettering Cancer Centre, Johns Hopkins University, The University of Sydney, The Westmead Institute for Medical Research, Centre Leon Berard, BC Cancer, part of Provincial Health Services Authority, University of Otago, and the University of Edinburgh
• Cancer Research-UK Scotland Centre, UK (Edinburgh and Glasgow Ovarian Cancer Group): Prof Owen Samson, Dr Patricia Roxburgh, Dr Ros Glasspool, Dr Seth Coffelt, Dr David Millan and Dr Gareth Bryson.
• Cancer Research-UK Scotland Centre/ Wellbeing of Women/Artios: Dr Patricia Roxburgh
• Stanford Women Cancer Centre, Stanford University. Stanford, California: Professor Amer Karam
• Peter MacCallum Cancer Centre, Melbourne, Australia: Professor Ian Campbell and Dr Kylie Gorringe.
• University of Sydney, Sydney, Australia: Professor Anna de Fazio.
• Netherlands Cancer Institute, Amsterdam, Netherlands: Dr Christianne Lok.
• The University of Texas MD Anderson Cancer Centre: Professor David M. Gershenson, MD

• Nicola Murray foundation: Charitable donation
• Cancer Research UK: Core funding, research grants and PhD fellowships.
• Wellbeing of Women/Artios: Research Grant
• University College London Clinical Trials Unit/Cancer Research-UK/Astra Zeneca: ICON9 clinical trial and related translational research
• AstraZeneca/Scottish Chief Scientist Office/Scottish Genome Partnership: Research grant.
• AbbVie :  Research Grant
• Target Ovarian Cancer: Research Grant
• Low Grade Serous Ovarian Cancer Initiative